Peptilogics grabs $35.4m Series B

Peptilogics, a developer of novel peptide therapeutics, has secured $35.4 million in Series B financing.

Peptilogics, a developer of novel peptide therapeutics, has secured $35.4 million in Series B financing. Presight Capital led the round with participation from other investors that included Founders Fund as well as from existing investor Peter Thiel.

Source: Press Release